$300,000 investment supports highly innovative research on drug
DORVAL, QC, Dec. 4, 2012 /CNW/ - Novartis Pharmaceuticals Canada Inc.
has become the latest pharmaceutical company to partner in the
innovative Explore program of the CQDM, with an investment of $300,000.
Novartis is a significant contributor to Research & Development (R&D)
in Quebec and has invested approximately 30% of its total sales in the
province over the last 5 years.
The Explore program is an initiative launched in 2010 by the CQDM as way
of funding unconventional and highly innovative research projects that
could impact the drug discovery process. Projects funded by this
program must have the potential for a breakthrough discovery that could
lead to an important change in the current paradigm or conventional
"Novartis is very pleased to be joining the CQDM and its other
pharmaceutical industry partners in this very important program to
encourage cutting-edge pharmaceutical research in Quebec," said Dr.
Riad Sherif B., President of Novartis Pharmaceuticals Canada Inc. "The
Explore program is fully compatible with the Novartis objectives to
discover, develop and successfully market innovative products to
prevent and cure disease, to ease suffering and to enhance quality of
Globally, the biopharmaceutical research model is rapidly evolving to
become more efficient and to optimize resources in the very expensive
and risky endeavor of drug development. Increasingly, research activity
is being conducted as collaborations with companies, research
institutions and governments. The CQDM is a public-private partnership
created four years ago as a new means to express Quebec's leadership in
biopharmaceutical research and now counts seven pharmaceutical company
"We are very pleased to welcome Novartis as a partner in our Explore
program to help ensure its ongoing success," said Diane Gosselin,
President and CEO of CQDM. "This has rapidly become an important means
for Quebec researchers with new ideas to secure funding to pursue their
innovative approaches. Not every idea will succeed, however we need
programs like Explore to uncover those promising ideas and to find new
innovative approaches to managing disease."
About the CQDM Explore Program
The Explore Program of the CQDM is a funding initiative for breakthrough
technologies that have the potential to significantly improve the drug
discovery or development process. It is aimed at supporting "smaller"
projects that may carry more than the usual degree of scientific risk,
and reinforce the commitment of the CQDM and its pharmaceutical company
members to funding disruptive research. The Explore Program is
dedicated to early-concept validation and technical feasibility of
creative or innovative ideas that when fully developed may address some
of the most important bottlenecks faced by the pharmaceutical industry
in the drug R&D process.
The Explore Program is open to the research community in Quebec from
both public and private research institutions. Following an annual call
for proposals, selected projects are eligible for up to $150,000 per
year per project for two years. Each winning project is also assigned
at least one mentor from the CQDM pharma members to ensure the
commercial viability of projects and that they are aligned with
industry needs. The three winning 2012 projects were announced in
CQDM is a meeting ground for all stakeholders in biopharmaceutical
research. Its principal mission is to fund research projects carried
out in partnership between the academic and private sectors. An
innovative Canadian initiative, CQDM has a two-fold goal: to accelerate
the drug discovery process and to develop safer and more effective
drugs. CQDM is funded through contributions from Pfizer Canada,
AstraZeneca, Merck, Boehringer Ingelheim (Canada) Ltd., GlaxoSmithKline
Inc., Eli Lilly Canada Inc., Novartis Pharmaceutical Canada Inc., the
Business-Led Networks of Centres of Excellence (BL-NCE) and the
Ministère de l'Enseignement supérieur, de la Recherche, de la Science
et de la Technologie du Québec. For more information: www.cqdm.org.
About Novartis Pharmaceuticals Canada Inc.
Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field,
is committed to the discovery, development and marketing of innovative
products to improve the well-being of all Canadians. In 2011, the
company invested close to $100 million in research and development in
Canada. Novartis Pharmaceuticals Canada Inc. employs more than 600
people in Canada. It was named for the seventh time as one of the "50
Best Employers in Canada" for 2011. For further information, please
SOURCE: Novartis Pharmaceuticals Canada Inc.
For further information:
Andrea Gilpin, Ph.D, MBA
Director, Corporate Communications
Novartis Pharmaceuticals Canada Inc.
514 631-6775 ext. 3356